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28%), so we have a good survival at 5 years in P2 (OS: 75% vs 58%, EFS: 
73% vs 55% DFS: 79% vs 68%).
Summary and Conclusions: Childhood ALL in our institut were characterized 
by a poor presentation at diagnosis: male sex, leucocytosis more than 100 G/L, 
T phenotype and bad response to prophase are frequent compared to the Occi­
dent reports. EFS are acceptable in our study but still less than observed in lit­
erature (85-90%). We have noted an improvement in the survival rates during 
the second period P2 this could be explained by improved support treatment
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WHAT IF YOU FAIL? IMPACT OF UNSUCCESSFUL CYTOGENETIC ANALYSIS 
ON TREATMENT OUTCOMES IN ACUTE LYMPHOBLASTIC LEUKEMIA  
(ALL): A  TERTIARY CARE SINGLE CENTRE ANALYSIS FROM INDIA
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Background: Cytogenetic findings are important in predicting prognosis; and 
are an obligatory tool in stratifying patients for treatment assignment in ALL. 
The large studies in ALL have reported between 10-30% of cytogenetic failure. 
The impact of cytogenetic failure on treatment outcomes in this group with ALL 
has not been sufficiently explored.
Aims: To determine the differences in clinical features and treatment outcomes 
in patients with ALL based on the success of karyotype analyses.
Methods: We undertook a retrospective study to evaluate the impact of cyto­
genetic failure on treatment outcomes in patients with a diagnosis of ALL (Burkitt- 
excluded) treated at our tertiary care center from January 2009 till December 
2014. Cytogenetic failure was used to define analyses that could not be per­
formed in the laboratory due to no mitoses or non-informative morphology. Risk 
stratification and treatment was based on the BFM95 protocol for patients’ <15 
years and GMALL in the older patients. Standard of care diagnostic tests and 
supportive care was administered to all patients. The cytogenetic data was 
retrieved from the original reports of the laboratory performing the analyses at 
our centre. Only cytogenetic studies sent to the laboratory were included for 
analyses. Clinical details were ascertained through patient admission records 
and discharge cards. The collected data was analyzed using SPSS.
A: OS Ьт L i r p t j p t ,  B: EFS h r  E im t jp *
C: OS by K*rr»tvp* iK ( tu ;  D: ITS  by K trrotrp* :«cck;
Figure 1.
Table 1. Socio-demographic characters, clinical features and laboratory 
parameters in newly diagnosed patients (N=54).
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Results: A total of 76 admitted patients were diagnosed with ALL. Of these 54 
(71.1 %) continued with treatment. Bone marrow was sent for cytogenetic analy­
ses in 33 of these patients. There were no significant differences observed in 
terms of socio-demographic and baseline laboratory parameters among the 
two groups based on the success of cytogenetic analyses (tablel).The Event 
Free Survival (EFS) and Overall Survival (OS) were lesser in patients with cyto­
genetic failure than in those who had a successful karyotype analyses (Figure 
1). With a mean follow up of 32 months, the EFS at one year in those with cyto­
genetic failure was significantly lower than those with a successful karyotype 
analyses (P=0.008). When compared against the outcomes of patients with 
adverse karyotype (t (9; 22) or >3 abnormalities), those with cytogenetic failure 
had a significantly lower EFS (P=0.022).
Summary and Conclusions: Risk stratification in ALL has not defined the opti­
mal strategy in patients with cytogenetic failure. Unsuccessful cytogenetics 
likely predicts a poor outcome. This needs to be further explored by facilitating 
the inclusion of these patients as a group in clinical trials.
PB1607
THE FREE RADICAL OXIDATION ROLE IN THE DEVELOPMENT OF 
ANTHRACYCLINE-INDUCED CARDIOTOXICITY IN PATIENTS WITH 
ACUTE LEUKEMIA IN THE PRESENCE OF CONCOMITANT ISCHEMIC 
HEART DISEASE
T. Lymanets1-* I. Skrypnyk1, G. Maslova1,
1Chair of Internal Medicine #1, Ukrainian Medical Stomatological Academy, 
Poltava, Ukraine
Background: Anthracycline antibiotics (AA) are included into the most modern 
acute leukemia (AL) treatment regimens. The AA assignment in polychemother­
apy (PCT) programs contributes to the clinical-hematological remission per­
centage growth, and the improvement of pts survival. However, the formation 
of anthracycline-induced cardiotoxic effects can be significant limiting factor of 
PCT full dose conducting, which certainly leads to reduced effectiveness of 
anticancer therapy. In this aspect particularly important becomes the assess­
ment of the heart tissue injuries potential risks. The incidence of cardiotoxicity 
depends on the cumulative dose (CD) of AA. The generally toxic AA CD is 550 
mg/m2 for doxorubicin. An additional risk factor for anthracycline cardiotoxicity 
is considered to be the concomitant ischemic heart disease (IHD). The imbal­
ance between generation and inactivation mechanisms of aggressive free rad­
icals as a risk factor of heart tissue AA-induced injury in patients with AL with 
concomitant ischemic heart disease remain insufficiently studied.
Aims: To assess the prooxidant-antioxidant imbalance status in patients with 
AL in the dynamics of AA treatment taking into account concomitant IHD. 
Methods: The study involved 41 patients with acute leukemia (acute lym­
phoblastic leukemia-13 pts, acute myeloid leukemia-28 pts), aged 16-72 years, 
23 (56%) men and 18 (44%) women, which PCT included AA. Patients were 
divided into two groups according to the presence of concomitant IHD: I (n=24) 
-  without concomitant IHD; II (n=17) -  with the concomitant IHD. The general 
condition assessment of pts of the both groups was performed twice: before 
specific therapy and after reaching AA cumulative dose from 100 to 200 mg/m2. 
The POL processes activity was determined by the malondialdehyde (MDA) 
level, the antioxidant protection (AOP) -  the serum catalase concentration. 
Results: Before treatment in patients of group I without concomitant IHD the 
MDA concentration in serum exceeded the upper limit of normal in 1.2 times, 
the catalase level -  in 1.1 times. In patients of group II with concomitant IHD the 
MDA level was increased in 1.46 times with the simultaneous tendency to reduce 
the catalase concentration in serum compared to normal, indicating that the 
exhaustion of antioxidant protection on the IHD background. Upon reaching the 
AACD of 100-200 mg/m2 MDA concentration in serum was in 1.54 times higher 
in pts of group II compared with pts of group I (4.81 ±0.38 mmol/l vs 3.12±0.28 
mmol/l; P<0.05). Simultaneously, with the presence of concomitant IHD in pts 
of group II the catalase level in serum was in 2.1 times lower in comparison with 
pts of group I (72.5±8.7 mkkat/l vs 33.8±3.2 mkkat/l; P<0.05).
Summary and Conclusions: Therefore, concomitant ischemic heart disease 
in patients with AL during the treatment AA is an additional risk factor for car­
diotoxicity, due to exhaustion antioxidant protection system and deepening 
imbalance between the formation and inactivation of free radicals.
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62 CASES
F. |V  M. Medhaffar1, В. A. I1, H. S1, К. О1, B. H1, K. F1, E. M1 
1 Hematology, Hedi Chaker Hospital, Sfax, Tunisia
Background: Several retrospective studies have confirmed that adolescents 
and young adults (AyA) with acute lymphoblastic leukemia (ALL) treated with 
pediatric protocols have better outcomes than similarly aged patients treated 
with adult protocols. We reported results and feasibility of a pediatric-based 
protocol (EORTC 58951) in adolescents and young adults.
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